Quest Diagnostics Inc. vs. Exagen Inc. Common Stock
Quest Diagnostics Inc. (DGX) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| DGX | XGN | |
|---|---|---|
| Market Cap | $27.20 billion | $203.74 million |
| Revenue (TTM) | $11.56 billion | $71.12 million |
| Net Income (TTM) | $1.11 billion | $-18,923,000 |
DGX leads on 3 of 3 size & scale factors.
Valuation
| DGX | XGN | |
|---|---|---|
| P/E Ratio | 26.16 | — |
| Price / Book | 3.48 | 16.68 |
| Price / Sales | 2.35 | 2.86 |
DGX leads on 2 of 2 valuation factors.
Profitability
| DGX | XGN | |
|---|---|---|
| Net Margin | 9.63% | -26.61% |
| Return on Equity | 14.23% | -154.90% |
DGX leads on 2 of 2 profitability factors.
Dividend
| DGX | XGN | |
|---|---|---|
| Dividend Yield | 1.40% | — |
| Payout Ratio | 36.52 | — |
DGX and XGN split the dividend factors evenly.
Risk & Sentiment
| DGX | XGN | |
|---|---|---|
| Short Interest | 4.76% | 0.02% |
XGN leads on 1 of 1 risk & sentiment factors.
Dig deeper: DGX overview, DGX financials, XGN overview, XGN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.